New analyses from VESALIUS-CV and the FOURIER open-label extension add stroke and long-term outcome data for evolocumab.

Biykem Bozkurt, MD, PhD, explains why survodutide, a glucagon and GLP-1 dual agonist, needed a cardiovascular safety trial in patients with obesity.

SCOUT-HCM 56-week data show sustained LVOT gradient reductions with mavacamten and no LVEF below 50% in adolescents with obstructive HCM.

Curing vitiligo isn't currently possible, and Dr. Desai says saying so plainly builds trust. He explains how he sets realistic, patient-specific goals around activity control and repigmentation.

The University of Exeter’s David Halpin, MA, DPhil, explains why GOLD 2026 treats a single COPD exacerbation as a trigger to ...

First-line IVF produced more live births than IUI within 7 months in couples with unexplained infertility.

The FDA granted accelerated approval to amivantamab and hyaluronidase for previously treated recurrent or metastatic head and ...

Two decades ago, lung cancer was treated almost exclusively with cytotoxic chemotherapy. Today, immune checkpoint inhibitors anchor treatment regimens across nearly every stage of the disease, ...

The glucagon/GLP-1 dual agonist is noninferior to placebo for major adverse cardiovascular events and lowers blood pressure ...

Michael Mina, MD, PhD, on why babies, immunocompromised patients, and the unvaccinated have the greatest need for a measles ...

Most patients with MASH stay on resmetirom at 1 year, but Medicaid coverage was tied to lower odds of filling a first ...

Gut-derived bile acids disrupt liver metabolism through LRH-1 before visible damage, pointing to new early biomarkers for ...